Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RBP4 | P02753 | 4/20 | 0.56 |
| ▸ | HCRTR1 | O43613 | 9/20 | 0.47 |
| ▸ | HCRTR2 | O43614 | 9/20 | 0.47 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.40 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.40 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.40 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16124187 | 0.81 | RBP4 (0.57) | RBP4HCRTR1HCRTR2TRPV1HSD11B1 | |
| SCHEMBL17454227 | 0.81 | RBP4 (0.58) | RBP4 | |
| SCHEMBL17518290 | 0.81 | RBP4 (0.55) | RBP4HCRTR1HCRTR2TRPV1AKR1C3 | |
| SCHEMBL17454226 | 0.81 | RBP4 (0.58) | RBP4 | |
| SCHEMBL16123861 | 0.81 | RBP4 (0.55) | RBP4HCRTR1HCRTR2TRPV1CHRNB2 | |
| SCHEMBL16127288 | 0.81 | RBP4 (0.58) | RBP4 | |
| SCHEMBL16127179 | 0.81 | RBP4 (0.58) | RBP4 | |
| SCHEMBL1394196 | 0.78 | RBP4 (0.57) | RBP4HCRTR1HCRTR2TRPV1AKR1C3 | |
| SCHEMBL17515569 | 0.77 | RBP4 (0.58) | RBP4HCRTR1HCRTR2TRPV1AKR1C3 | |
| SCHEMBL16124179 | 0.76 | RBP4 (0.52) | RBP4HCRTR1HCRTR2TRPV1HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230241049-A1 | RBP4 ANTAGONISTS FOR TREATMENT AND PREVENTION OF NON-ALCOHOLIC FATTY LIVER DISEASE AND GOUT | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-08-03 | — | — | US | disclosed |
| US-20230241049-A1 | RBP4 ANTAGONISTS FOR TREATMENT AND PREVENTION OF NON-ALCOHOLIC FATTY LIVER DISEASE AND GOUT | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-08-03 | — | — | US | disclosed |
| US-10787453-B2 | Octahydropyrrolopyrroles their preparation and use | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2020-09-29 | — | — | US | disclosed |
| WO-2020028723-A1 | RBP4 ANTAGONISTS FOR TREATMENT AND PREVENTION OF NON-ALCOHOLIC FATTY LIVER DISEASE AND GOUT | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2020-02-06 | — | — | WO | disclosed |
| US-9944644-B2 | Octahydropyrrolopyrroles their preparation and use | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2018-04-17 | — | — | US | disclosed |
| US-9944644-B2 | Octahydropyrrolopyrroles their preparation and use | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2018-04-17 | — | — | US | disclosed |
| US-20160046632-A1 | OCTAHYDROPYRROLOPYRROLES THEIR PREPARATION AND USE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2016-02-18 | — | — | US | disclosed |
| US-20160046632-A1 | OCTAHYDROPYRROLOPYRROLES THEIR PREPARATION AND USE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2016-02-18 | — | — | US | disclosed |
| WO-2014151936-A9 | OCTAHYDROPYRROLOPYRROLES, THEIR PREPARATION AND USE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2015-06-25 | — | — | WO | disclosed |
| WO-2014151936-A1 | OCTAHYDROPYRROLOPYRROLES, THEIR PREPARATION AND USE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2014-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160046632-A1 | OCTAHYDROPYRROLOPYRROLES THEIR PREPARATION AND USE | QDPR, DPYD, DHPS | RBP4 4178/4885HCRTR1 995/4885HCRTR2 517/4885 |
| US-20230241049-A1 | RBP4 ANTAGONISTS FOR TREATMENT AND PREVENTION OF NON-ALCOHOLIC FATTY LIVER DISEASE AND GOUT | RBP4, RBP1, FABP1 | RBP4 1/4885HCRTR1 2204/4885HCRTR2 1872/4885 |
| US-10787453-B2 | Octahydropyrrolopyrroles their preparation and use | QDPR, DPYD, DHPS | RBP4 4178/4885HCRTR1 995/4885HCRTR2 517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.